Fuji Pharma Co., Ltd. (FRA:FUP)

Market Cap	199.47M
Revenue (ttm)	301.78M
Net Income (ttm)	19.62M
Shares Out	n/a
EPS (ttm)	0.81
PE Ratio	10.17
Forward PE	n/a
Dividend	0.26 (3.25%)
Ex-Dividend Date	Mar 28, 2025

Volume	n/a
Average Volume	n/a
Open	8.00
Previous Close	8.05
Day's Range	8.00 - 8.00
52-Week Range	7.05 - 10.30
Beta	n/a
RSI	66.74
Earnings Date	Aug 7, 2025

About Intra-Cellular Therapies

Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women, in vitro diagnostics, acute medical care products, and curative medicines, as well as information regarding pharmaceuticals and health; and contract manufacturing services. Fuji Pharma Co., Ltd. was founded in 1959 and is headquartered in Tokyo, Japan.

• Industry: Pharmaceutical Preparations
• Founded: 1959
• Employees: 1,658
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: FUP

Financial Performance

In 2024, Fuji Pharma's revenue was 46.14 billion, an increase of 12.84% compared to the previous year's 40.89 billion. Earnings were 6.15 billion, an increase of 78.92%.